Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Return on Equity: 2021-2023

Historic Return on Equity for Candel Therapeutics (CADL) over the last 2 years, with Sep 2023 value amounting to -1.35%.

  • Candel Therapeutics' Return on Equity fell 73.00% to -1.35% in Q3 2023 from the same period last year, while for Sep 2023 it was -1.35%, marking a year-over-year decrease of 73.00%. This contributed to the annual value of -0.63% for FY2022, which is 64.00% up from last year.
  • Candel Therapeutics' Return on Equity amounted to -1.35% in Q3 2023, which was down 30.81% from -1.03% recorded in Q2 2023.
  • Candel Therapeutics' Return on Equity's 5-year high stood at -0.41% during Q4 2021, with a 5-year trough of -2.43% in Q3 2021.
  • Over the past 3 years, Candel Therapeutics' median Return on Equity value was -0.70% (recorded in 2022), while the average stood at -0.93%.
  • Per our database at Business Quant, Candel Therapeutics' Return on Equity skyrocketed by 181bps in 2022 and then slumped by 73bps in 2023.
  • Quarterly analysis of 3 years shows Candel Therapeutics' Return on Equity stood at -0.41% in 2021, then fell by 29bps to -0.70% in 2022, then plummeted by 73bps to -1.35% in 2023.
  • Its Return on Equity was -1.35% in Q3 2023, compared to -1.03% in Q2 2023 and -0.81% in Q1 2023.